future competition landscape: who can seize the opportunity?

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

in recent years, american companies have continuously made breakthroughs in the market with huge funds and perfect business models, becoming the leader in the field of innovative drugs. they have huge resources and experience and have successfully brought new drugs to the global market. chinese innovative pharmaceutical companies are in a dilemma between exploration and opportunity, and it is crucial to use their own advantages to achieve breakthroughs.

the success of ivosi is the best example. it broke through the strict clinical development standards, gained a significant market share, and eventually attracted the attention and investment of mncs. this model also inspired other innovative pharmaceutical companies: only by achieving success in "head-to-head" studies can they win the competition in the international market.

the success of akeso biotech is even more outstanding. with its strong r&d capabilities and strategic cooperation, it has transformed its own advantages into market advantages and become the focus of the international market. akeso biotech's successful model is worth learning and reference for all chinese biotech companies.

however, kangfang biopharma's road to success is not simple, and it faces huge challenges. the competition from mncs is fierce, and the market share distribution is also very complicated. how to cooperate with them and achieve balanced development is a huge test for kangfang biopharma.

where will the focus of the future competitive landscape be?

• mnc's "blockbuster" strategy: they need to rely on new "blockbuster" drugs to deal with the risk of product patent expiration and find development paths for breakthrough innovative drugs.
• akeso's international market breakthrough: they need to build their own brand and influence in the global market and seek cooperation with mncs to further expand their market share.
• the future development of innovative drugs in china: how can we leverage our own strengths, seize opportunities, and cooperate with mncs to create stronger competitiveness?

ultimately, who succeeds will depend on their sensitivity to market changes, precision in risk management, and the depth and flexibility of their partnerships.